N-(2-adamantyl)-2,3-dihydrospiro[indene-1,4'-piperidine]-1'-carboxamide | 1009373-43-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: N-(2-adamantyl)-2,3-dihydrospiro[indene-1,4'-piperidine]-1'-carboxamide
• 英文别名: N-(adamantan-2-yl)-2,3-dihydrospiro[indene-1,4''-piperidine]-1''-carboxamide；N-(2-adamantyl)spiro[1,2-dihydroindene-3,4'-piperidine]-1'-carboxamide
• CAS: 1009373-43-6
• 化学式: C₂₄H₃₂N₂O
• 分子量: 364.531
• InChiKey: LQODPNODUZWIMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  27
• 可旋转键数：
  1
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,3-二氢螺(茚-1,4-哌啶) 、 2-adamantyl isocyanate 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(2-adamantyl)-2,3-dihydrospiro[indene-1,4'-piperidine]-1'-carboxamide
  参考文献：
  名称：

  Spirocyclic ureas: Orally bioavailable 11β-HSD1 inhibitors identified by computer-aided drug design

  摘要：

  Structure-guided drug design led to the identification of a class of spirocyclic ureas which potently inhibit human 11 beta-HSD1 in vitro. Lead compound 10j was shown to be orally bioavailable in three species, distributed into adipose tissue in the mouse, and its (R) isomer 10j2 was efficacious in a primate pharmacodynamic model. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.082

文献信息

• INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
  申请人：Claremon David A.

  公开号：US20110034455A1

  公开（公告）日：2011-02-10

  This invention relates to novel compounds of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

  这项发明涉及到式(I*)的新化合物，其药用盐以及药物组合物，这些化合物对于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病是有用的。该发明还涉及这些新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质醇酮转化为皮质醇的方法。
• US8927715B2
  申请人：——

  公开号：US8927715B2

  公开（公告）日：2015-01-06
• Spirocyclic ureas: Orally bioavailable 11β-HSD1 inhibitors identified by computer-aided drug design
  作者：Colin M. Tice、Wei Zhao、Zhenrong Xu、Salvacion T. Cacatian、Robert D. Simpson、Yuan-Jie Ye、Suresh B. Singh、Brian M. McKeever、Peter Lindblom、Joan Guo、Paula M. Krosky、Barbara A. Kruk、Jennifer Berbaum、Richard K. Harrison、Judith J. Johnson、Yuri Bukhtiyarov、Reshma Panemangalore、Boyd B. Scott、Yi Zhao、Joseph G. Bruno、Linghang Zhuang、Gerard M. McGeehan、Wei He、David A. Claremon

  DOI：10.1016/j.bmcl.2009.12.082

  日期：2010.2

  Structure-guided drug design led to the identification of a class of spirocyclic ureas which potently inhibit human 11 beta-HSD1 in vitro. Lead compound 10j was shown to be orally bioavailable in three species, distributed into adipose tissue in the mouse, and its (R) isomer 10j2 was efficacious in a primate pharmacodynamic model. (C) 2009 Elsevier Ltd. All rights reserved.